Carbon letters

  • Volume 27
  • /
  • Pages.18-25
  • /
  • 2018
  • /
  • 1976-4251(pISSN)
  • /
  • 2233-4998(eISSN)
Korean Carbon Society (한국탄소학회)
권호 표지
DOI QR코드

DOI QR Code

Graphene nanosheets encapsulated poorly soluble drugs with an enhanced dissolution rate

  • Shen, Shou-Cang (Institute of Chemical and Engineering Sciences, A*STAR (Agency for Science, Technology and Research)) ;
  • Ng, Wai Kiong (Institute of Chemical and Engineering Sciences, A*STAR (Agency for Science, Technology and Research)) ;
  • Letchmanan, Kumaran (Institute of Chemical and Engineering Sciences, A*STAR (Agency for Science, Technology and Research)) ;
  • Lim, Ron Tau Yee (Institute of Chemical and Engineering Sciences, A*STAR (Agency for Science, Technology and Research)) ;
  • Tan, Reginald Beng Hee (Institute of Chemical and Engineering Sciences, A*STAR (Agency for Science, Technology and Research))
  • Received : 2017.12.06
  • Accepted : 2018.01.04
  • Published : 2018.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

In this study, graphene oxide(GO) was used as drug carriers to amorphize poorly watersoluble drugs via a co-spray drying process. Two poorly water-soluble drugs, fenofibrate and ibuprofen, were investigated. It was found that the drug molecules could be in the graphene nanosheets in amorphous or nano crystalline forms and thus have a significantly enhanced dissolution rate compared with the counterpart crystalline form. In addition, the dissolution of the amorphous drug enwrapped with the graphene oxide was higher than that of the amorphous drug in activated carbon (AC) even though the AC possessed a larger specific surface area than that of the graphene oxide. The amorphous formulations also remained stable under accelerated storage conditions ($40^{\circ}C$ and 75% relative humidity) for a study period of 14 months. Therefore, graphene oxide could be a potential drug carrier and amorphization agent for poorly water-soluble drugs to enhance their bioavailability.

Keywords

References

  1. Toda K, Furue, R, Hayami S. Recent progress in applications of graphene oxide for gas sensing: a review. Anal Chim Acta, 878, 43 (2015). https://doi.org/10.1016/j.aca.2015.02.002.
  2. Chabot V, Higgins D, Yu AP, Xiao XC, Chen ZW, Zhang JJ. A review of graphene and graphene oxide sponge: material synthesis and applications to energy and the environment. Energy Environ Sci, 7, 1564 (2014). https://doi.org/10.1039/c3ee43385d.
  3. OuYang FP, Huang B, Li ZY, Xiao J, Wang HY, Xu H. Chemical functionalization of graphene nanoribbons by carboxyl groups on Stone-Wales defects. J Phys Chem C, 112, 12003 (2008). https://doi.org/10.1021/jp710547x.
  4. Zhu SM, Li JB, Chen YH, Chen ZX, Chen CX, Li Y, Cui ZW, Zhang D. Grafting of graphene oxide with stimuli-responsive polymers by using ATRP for drug release. J Nanopart Res, 14, 1132 (2012). https://doi.org/10.1007/s11051-012-1132-x.
  5. Wang XM, Zhang WH. Application of graphene derivatives in cancer therapy: a review. New Carbon Mater, 28, 321 (2013).
  6. Liu JG, Cui L, Losic D. Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater, 9, 9243 (2013). https://doi.org/10.1016/j.actbio.2013.08.016.
  7. Yang K, Feng LZ, Liu Z. The advancing uses of nano-graphene in drug delivery. Expert Opin Drug Delivery, 12, 601 (2014). https://doi.org/10.1517/17425247.2015.978760.
  8. Mianehrow H, Moghadam MHM, Sharif F, Mazinani S. Grapheneoxide stabilization in electrolyte solutions using hydroxyethyl cellulose for drug delivery application. Int J Pharm, 484, 276 (2015). https://doi.org/10.1016/j.ijpharm.2015.02.069.
  9. Hou L, Shi YY, Jiang GX, Liu W, Han HL, Feng QH, Ren JX, Yuan YJ, Wang YC, Shi JJ, Zhang ZZ. Smart nanocomposite hydrogels based on azo crosslinked graphene oxide for oral colonspecific drug delivery. Nanotech, 27, 315105 (2016). https://doi.org/10.1088/0957-4484/27/31/315105.
  10. Mianehrow H, Afshari R, Mazinani S, Sharif F, Abdouss M. Introducing a highly dispersed reduced graphene oxide nano-biohybrid employing chitosan/hydroxyethyl cellulose for controlled drug delivery. Int J Pharm, 509, 400 (2016). https://doi.org/10.1016/j.ijpharm.2016.06.015.
  11. Wang WN, He X. Aerosol processing of crumpled graphene oxidebased nanocomposites for drug delivery. Curr Pharm Des, 22, 2491 (2016). https://doi.org/10.2174/1381612822666160128145456.
  12. Ma NX, Zhang BH, Liu J, Zhang P, Li ZB, Luan YX. Green fabricated reduced graphene oxide: evaluation of its application as nano-carrier for pH-sensitive drug delivery. Int J Pharm, 496, 984 (2015). https://doi.org/10.1016/j.ijpharm.2015.10.081.
  13. Zheng XT, Ma XQ, Li CM. Highly efficient nuclear delivery of anti-cancer drugs using a bio-functionalized reduced graphene oxide. J Colloid Interface Sci, 467, 35 (2016). https://doi.org/10.1016/j.jcis.2015.12.052.
  14. Wei YC, Zhou FF, Zhang, Chen Q, Xing D. A graphene oxide based smart drug delivery system for tumor mitochondria-targeting photodynamic therapy. Nanoscale, 8, 3530 (2016). https://doi.org/10.1039/c5nr07785k.
  15. Tian JW, Luo YP, Huang LW, Feng YQ, Ju HX, Yu BY. Pegylated folate and peptide-decorated graphene oxide nanovehicle for in vivo targeted delivery of anticancer drugs and therapeutic selfmonitoring. Biosens Bioelectron, 80, 519 (2016). https://doi.org/10.1016/j.bios.2016.02.018.
  16. Wang GS, Ma YY, Wei ZY, Qi M. Development of multifunctional cobalt ferrite/graphene oxide nanocomposites for magnetic resonance imaging and controlled drug delivery. Chem Eng J, 289, 150 (2015). https://doi.org/10.1016/j.cej.2015.12.072.
  17. Yang Y, Shi HL, Wang YP, Shi BZ, Guo LL, Wu DM, Yang SP, Wu HX. Graphene oxide/manganese ferrite nanohybrids for magnetic resonance imaging, photothermal therapy and drug delivery. J Biomater Appl, 30, 810 (2016). https://doi.org/10.1177/0885328215601926.
  18. Justin R, Tao K, Roman S, Chen DX, Xu YW, Geng XS, Ross IM, Grant RT, Pearson A, Zhou GD, MacNeil S, Sun K, Chen BQ. Photoluminescent and superparamagnetic reduced graphene oxide-iron oxide quantum dots for dual-modality imaging, drug delivery and photothermal therapy. Carbon, 97, 54 (2016). https://doi.org/10.1016/j.carbon.2015.06.070.
  19. Li B, Yang J, Huang Q, Zhang Y, Peng C, Zhang Y, He Y, Shi JY, Li WX, Hu J, Fan CH. Biodistribution and pulmonary toxicity of intratracheally instilled graphene oxide in mice. NPG Asia Mater, 5, e44 (2013). https://doi.org/10.1038/am.2013.7.
  20. Schinwald A, Murphy F, Askounis A, Koutsos V, Sefiane K, Donaldson K, Campbell CJ. Minimal oxidation and inflammogenicity of pristine graphene with residence in the lung. Nanotoxicology, 8, 824 (2013). https://doi.org/10.3109/17435390.2013.831502.
  21. Schinwald A, Murphy FA, Jones A, Macnee W, Donaldson K. Graphene-based nanoplatelets: a new risk to the respiratory system as a consequence of their unusual aerodynamic properties. ACS Nano, 6, 736 (2012). https://doi.org/10.1021/nn204229f.
  22. Yang K, Gong H, Shi X, Wan J, Zhang Y, Liu Z. In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration. Biomaterials, 34, 2787 (2013). https://doi.org/10.1016/j.biomaterials.2013.01.001.
  23. Fu C, Liu T, Li L, Liu H, Liang Q, Meng X. Effects of graphene oxide on the development of offspring mice in lactation period. Biomaterials, 40, 23 (2015). https://doi.org/10.1016/j.biomaterials.2014.11.014.
  24. Santos H, Peltonen L, Limnell T, Hirvonen J. Mesoporous materials and nanocrystals for enhancing the dissolution behavior of poorly water-soluble drugs. Curr Pharm Biotechnol, 14, 926 (2013). https://doi.org/10.2174/1389201014666131226150404.
  25. Vialpando M, Martens, JA, Van den Mooter G. Potential of ordered mesoporous silica for oral delivery of poorly soluble drugs. Ther Delivery, 2, 1079 (2011). https://doi.org/10.4155/tde.11.66.
  26. Shen SC, Ng WK, Chia LO, Dong YC, Tan RH. Applications of mesoporous materials as excipients for innovative drug delivery and formulation. Curr Pharm Des, 19, 6270 (2013). https://doi.org/10.2174/1381612811319350005.
  27. Zhao P, Wang LH, Sun CS, Jiang TY, Zhang JH, Zhang Q, Sun J, Deng YH, Wang SL. Uniform mesoporous carbon as a carrier for poorly water soluble drug and its cytotoxicity study. Eur J Pharm Biopharm, 80, 535 (2012). https://doi.org/10.1016/j.ejpb.2011.12.002.
  28. McCarthy CA, Ahern RJ, Dontireddy R, Ryan KB, Crean AM. Mesoporous silica formulation strategies for drug dissolution enhancement: a review. Expert Opin Drug Delivery, 13, 93 (2016). https://doi.org/10.1517/17425247.2016.1100165.
  29. Hong SQ, Shen SC, Tan DCT, Ng WK, Liu XM, Chia LSO, Irwan AW, Tan R, Nowak SA, Marsh K, Gokhale R. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods. Drug Delivery, 23, 316 (2016). https://doi.org/10.3109/10717544.2014.913323.
  30. Lim RTY, Ng WK, Widjaja E, Tan RBH. Comparison of the physical stability and physicochemical properties of amorphous indomethacin prepared by co-milling and supercritical anti-solvent co-precipitation. J Supercritical Fluids, 79, 186 (2013). https://doi.org/10.1016/j.supflu.2013.02.017.
  31. Mestre AS, Pires RA, Aroso I, Fernandes EM, Pinto ML, Reis RL, Andrade MA, Pires J, Silva SP, Carvalho AP. Activated carbons prepared from industrial pre-treated cork: Sustainable adsorbents for pharmaceutical compounds removal. Chem Eng J, 253, 408 (2014). https://doi.org/10.1016/j.cej.2014.05.051.
  32. Bhadra BN, Ahmed I, Kim S, Jhung SH. Adsorptive removal of ibuprofen and diclofenac from water using metal-organic frame-work-derived porous carbon. Chem Eng J, 314, 50 (2017). https://doi.org/10.1016/j.cej.2016.12.127.
  33. Wu Q, Kennedy MT, Nagapudi K, Kiang YH. Humidity induced phase transformation of poloxamer 188 and its effect on physical stability of amorphous solid dispersion of AMG 579, a PDE10A inhibitor. Int J Pharm, 521, 1 (2017). https://doi.org/10.1016/j.ijpharm.2017.01.059.
  34. Marsac PJ, Konno H, Rumondor ACF, Taylor LS. Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water. Pharm Res, 25, 647 (2008). https://doi.org/10.1007/s11095-007-9420-3.
  35. Martinez-Oharriz MC, Rodriguez-Espinosa C, Martin C, Goni MM, Tros-Ilarduya MC, Sanchez M. Solid dispersions of diflunisal-PVP: polymorphic and amorphous states of the drug. Drug Dev Ind Pharm, 28, 717 (2002). https://doi.org/10.1081/ddc-120003864.
  36. Lim RTY, Ng WK, Tan RBH, Dissolution enhancement of indomethacin via amorphization using co-milling and supercritical coprecipitation processing. Powder Technol, 240, 79 (2013). https://doi.org/10.1016/j.powtec.2012.07.004.